<DOC>
	<DOCNO>NCT02390960</DOCNO>
	<brief_summary>This Phase 2a , single-dose , double-blind , placebo-controlled , 2-way crossover study men ED . A single 2 gram dose SST-6006 topical cream 5 % w/w ( formulate deliver 100 mg sildenafil ) topical placebo cream apply penile shaft glans . There 4 study phase : Initial Patient Screening Phase ( Visit 1 , Off Site 4-Week Run-in Period Visit 2 ) , Final Patient Screening Phase ( Visit 3 ) , SST-6006/Placebo Double-Blind Dosing Phase ( Visits 4-5 ) , Follow-up Phase . Primary outcomes evaluate Weeks 7 8 study</brief_summary>
	<brief_title>A Phase 2a , Single-Dose , Double-Blind , Placebo-Controlled , 2-Way Crossover Study Using Penile Plethysmography Evaluate Efficacy Safety SST-6006 , Topical Sildenafil Cream ( 5 % w/w ) , Compared Placebo Treatment Erectile Dysfunction</brief_title>
	<detailed_description>Initial Patient Eligibility : Visit 1 ( Day 1 ) After patient provide write informed consent , initial screening procedure perform . Patients meet eligibility criterion instruct completion SEP Diary , need one week washout ED medication start Off-Site 4-Week Run-In Period use ED medication prohibit throughout entire 4-week duration completion Visit 5 . Site staff contact patient phone 4 7 day follow Visit 1 ( Days 4- 7 ) communicate eligibility ( met laboratory parameter one week washout ) participate Off-Site 4-Week Run-In Period . Site staff also schedule Topical Placebo RigiScan Qualification Visit ( Visit 2 ) within two day completion 4-Week Run-In Period eligible patient . Ineligible patient instruct discard SEP Diary discontinue study participation Off-Site 4-Week Run-In Period ( Day 8-35 ) Eligible patient participate Off-Site 4-Week Run-In Period time attempt intercourse minimum 4 time . Use ED medication prohibit throughout entire 4-week duration completion Visit 5 . Patients ask maintain Sexual Encounter Profile ( SEP ) diary 4-Week Run-In Period complete intercourse attempt . Topical Placebo RigiScan Qualification : Visit 2 ( Day 36 [ + 2 day ] ) Patients successfully complete 4-Week Run-In instruct complete IIEF questionnaire begin Visit 2 . Eligible patient must document mild-moderate ED demonstrate score 11-21 International Index Erectile Function ( IIEF ) Erectile Function domain IIEF questionnaire . Eligible patient complete single-blind ( patient ) 60 minute plethysmography procedure use placebo cream familiarize patient plethysmography device ( i.e . RigiScan ) evaluate placebo response Visual Sexual Stimulation ( VSS ) . Patients demonstrate topical placebo response ( i.e . achieve erection ≥ 60 % rigidity base penis cumulative duration &gt; 4 minute ) ineligible study participation . Any patient adverse dermatologic reaction placebo cream exclude participation study follow normalization symptom . Safety data patient , regardless continued eligibility , include database patient expose IP ( placebo cream ) visit . There 7 ( ± 1 ) day washout period Visits 2 3 . Oral Sildenafil RigiScan Qualification : Visit 3 ( Day 43 [ ± 2 day ] ) Patients meet eligibility criterion complete Oral Sildenafil RigiScan Qualification visit , consist single-blind ( patient ) plethysmography procedure 60 minute VSS evaluate patient 's response oral sildenafil . Patients respond oral sildenafil ( i.e. , achieve ≥ 60 % rigidity base penis cumulative duration &gt; 15 minute EHS Score 3 4 ) exclude study participation . There 7 ( ± 1 ) day washout period Visit 3 Visit 4 ( i.e. , first visit SST-6006/Placebo Double-Blind Dosing Phase ) . SST-6006/Placebo Double-Blind Dosing Phase : Visits 4 &amp; 5 ( Days 50 57 [ ± 2 day ] ) Eligible patient randomize sequence dosing ( i.e. , placebo cream SST-6006 SST-6006 placebo cream ) . The SST-6006/Placebo Double-Blind Dosing Phase consist two plethysmography procedure 60 minute VSS . One evaluate patient 's response SST-6006 evaluate patient 's response placebo cream . Patients instruct complete 4-Point Erection Hardness Scale ( EHS ) immediately follow completion plethysmography procedure visit . There 7 ( ± 1 ) day wash-out Visit 4 Visit 5 .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Patient heterosexual male ≥ 18 ≤ 70 year age . 2 . Patient clinical diagnosis erectile dysfunction minimum 6 month . 3 . Patient body mass index ( BMI ) 18 30 kg/m² , inclusive . 5 . Patient capable understand comply protocol agree sign informed consent document . 6 Patient agrees use condoms sexual activity 7 day immediately follow visit involve application SST6006 placebo cream ( i.e . Visit 2 , Visit 4 Visit 5 ) . 7 . Patient testosterone level ≥ 300 ng/dL ( either naturally androgen replacement therapy ; androgen replacement therapy , must take ≥ 6 month ) . 8 . Patient willing undergo plethysmography procedure VSS trial Subject unfamiliar unwilling watch visual sexual stimulation ( VSS ) . 2 . Subject disorder history disorder may prevent successful completion study . 3 . Subjects abnormal physical exam , opinion Investigator , would interfere study participation . 4 . Subject significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , genitourinary , psychiatric disease unstable medical condition would contraindicate administration study medication , interfere study evaluation , limit study participation , contraindicate sexual activity , confound interpretation study result . 5 . Subject active ulcer clinically significant bleed disorder . 6 . Subject history myocardial infarction , stroke , lifethreatening arrhythmia within 6 month prior Visit 1 ; history coronary disease cause angina ; congestive heart failure require medical intervention . 7 . Subject uncontrolled hypertension untreated hypertension . 8 . Subject history orthostatic hypotension orthostatic hypotension . 9 . Subject unable walk two flight stair briskly without chest pain . 10 . Subject use alpha blocker . 11 . Subject use possession nitrate contain medication ( ) . 12 . Subject retinitis pigmentosa sickle cell anemia related anemia , even subject feel clinically well time screen . Subjects retinitis pigmentosa identify specifically ask whether condition , visual sign symptom condition ( include question subject whether difficulty see night low light , visual field deficit indicate loss peripheral central vision ) , family history . 13 . Subject anatomical deformation penis angulation , cavernosal fibrosis , Peyronie¡s disease , history genital surgery . 14 . Subject history prostate surgery . 15 . Subject history pelvic radiation . 16 . Subject type 1 type 2 diabetes . 17 . Subject history cancer basal cell carcinoma . 18 . Subject surgical medical condition may interfere absorption , distribution , metabolism , excretion test article . 19 . Subject history drug abuse within 1 year Visit 1 . 20 . Subject history alcoholism within 1 year Visit 1 , admit alcohol abuse , average consumption 2 standard unit alcohol per day ( standard unit equal 12 ounce beer , 1¨ö ounce 80proof alcohol , 6 ounce wine ) . 21 . Subject treatment currently within 1 month ( 28 day ) Visit 1 following : weak , moderate , strong inhibitor inducer CYP3A4 CYP2C9 enzyme ( e.g. , CYP3A4 : ketoconazole , clarithromycin , verapamil , diltiazem , St. John¡s Wort / CYP2C9 : fluconazole , oxandrolone , fluvastatin , metronidazole ) . Any prescription , overthecounter ( OTC ) medication , herbal product take recently currently take screen study personnel prior study enrollment confirm drug inhibit induce two enzyme list . If subject take prescription OTC drug direction health care provider inhibitor inducer CYP3A4 CYP2C9 , provider consult medication stop purpose study participation . 22 . Subject unwilling refrain use medication erectile dysfunction , exception study medication , Visit 1 throughout duration study completion Visit 5 . 23 . Subject positive finding urine drug screen ( e.g. , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates ) . 24 . Subjects positive alcohol breath test . 25 . Subject participate clinical research study evaluate another investigational drug therapy within 30 day Visit 1 . 26 . Subject unwilling refrain ingest grapefruit , grapefruitcontaining product , Seville oranges , product contain Seville orange ( e.g. , orange marmalade ) three day prior dose visit . 27 . Subject skin break , irritation , dermatosis , lesion penile area study cream apply . 28 . Subject know hypersensitivity allergy ingredient IP . 29 . Subject significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , genitourinary , unstable medical condition indicate laboratory result would contraindicate administration study medication , interfere study evaluation , limit study participation , contraindicate sexual activity , confound interpretation study result . 30 . Subjects abnormal laboratory parameter , opinion Investigator , could confound interpretation study result . 31 . Subjects positive serology finding sexually transmit infection ( i.e . syphilis , gonorrhea , chlamydia , HIV antibody , hepatitis b surface antigen ( HBsAg ) hepatitis c ( HCV ) antibody . 32 . Subjects abnormal vital sign and/or ECG result , opinion Investigator , would affect interpretation study result .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>